Pluripotent stem cell models of sporadic Alzheimer's Disease

散发性阿尔茨海默病的多能干细胞模型

基本信息

批准号：
8321504
负责人：
Lawrence S. Goldstein
金额：
$ 18.36万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-01 至 2013-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8321504
关键词：
Address Age Alzheimer&apos s Disease Alzheimer&apos s disease model Alzheimer&apos s disease risk Amyloid Amyloid beta-Protein Precursor Animal Model Asses Cell Culture Techniques Cell Line Cell model Cells Data Development Diagnostic Disease Drug Delivery Systems Exhibits Generations Genes Genetic Genetic Risk Genetic Variation Genome Genomics Human Human Genetics Human Genome Image In Vitro Individual Inflammatory Measures Methods Modeling Molecular Molecular Genetics Mus Mutation Neurofibrillary Tangles Neuroglia Neurologic Neurons Older Population Pathology Pathway interactions Patients Persons Phenotype Pilot Projects Pluripotent Stem Cells Poisoning Population Predisposition Presenile Alzheimer Dementia Public Health Resolution Risk Factors Rodent Role Technology Testing Therapeutic Transgenic Model Variant Work amyloid precursor protein processing base familial Alzheimer disease genetic analysis genetic manipulation genetic risk factor genetic variant genome wide association study induced pluripotent stem cell mutant neuron loss novel therapeutics overexpression oxidative damage presenilin-1 protein expression stem cell technology tau Proteins tau phosphorylation

项目摘要

DESCRIPTION (provided by applicant): How do the genomic variants in individuals with sporadic Alzheimer's Disease (SAD) contribute to the development of Alzheimer's Disease (AD)? To begin addressing this question human induced pluripotent stem cell (hIPSC) technology will be used to begin testing the hypothesis that the genomes of individual SAD patients contain genetic variants that generate biochemically detectable phenotypes in human neurons. Human pluripotent stem cells (hIPSC) allow the genomes of human individuals afflicted with SAD to be captured in a pluripotent stem cell line. Such cells can then be differentiated to human neurons or glia in vitro for evaluating whether the captured genome alters neuronal or glial phenotype in a manner similar to that seen in cells carrying FAD mutations or as predicted by mechanistic models of SAD such as the Ass hypothesis. An hIPSC model may also be useful for addressing human specific effects and avoiding some aspects of the well known limitations of animal models such as high copy number in transgenic models and the absence of a human genetic background. Our underlying hypothesis is that the genome of a patient with SAD contains a set of susceptibility variants that may alter neuronal, glial, or other relevant cellular phenotypes in a detectable manner. Broadly speaking, genomic variants in SAD patients could contribute to disease in a variety of ways ranging from effects on inflammatory pathways, glial turnover of Ass or other potentially toxic molecules generated by neurons and other cells, or by effects in neurons on pathways of APP processing, susceptibility to Ass poisoning, tau hyperphosphorylation, oxidative damage, etc. In this R21 exploratory proposal, we propose to take the first step and use hIPSC technology to test the hypothesis that at least some SAD genomes cause APP expression, APP processing, or tau phosphorylation phenotypes in human neurons that carry the genomes of patients who developed SAD. Identification of such genomes would provide the raw material for further studies using high resolution molecular genetic analyses to define how different genomic variants contribute to neuronal phenotypes and might allow new drug targets and pathways to be identified. Possible predictive measures and diagnostics might also be generated. In this pilot project, we will probe these issues by completing two specific aims: 1) We will generate 3 hIPSC lines each from 5 SAD patients and 5 age-matched normal controls (NC). 2) We will generate purified neurons from each hIPSC line and test whether SAD neurons exhibit APP expression, APP processing, or tau phosphorylation changes typical of FAD.

描述（由申请人提供）：零星阿尔茨海默氏病（SAD）患者的基因组变异如何有助于阿尔茨海默氏病（AD）的发展？为了开始解决这个问题，人类诱导的多能干细胞（HIPSC）技术将开始检验以下假设：个别SAD患者的基因组包含在人神经元中产生生物化学可检测到的生物化学检测表型的遗传变异。人多能干细胞（HIPSC）允许患有SAD的人的基因组在多能干细胞系中捕获。然后，可以在体外与人神经元或胶质区分开此类细胞，以评估捕获的基因组是否以类似于带有FAD突变的细胞或通过SAD的机械模型（例如Ass假设）预测的细胞中所见的方式来改变神经元或神经胶质表型。 HIPSC模型也可能有助于解决人类特异性效应，并避免动物模型众所周知的局限性的某些方面，例如转基因模型中的高拷贝数和缺乏人类遗传背景。我们的基本假设是，SAD患者的基因组包含一组可能以可检测方式改变神经元，神经胶质或其他相关细胞表型的敏感性变体。从广义上讲，SAD患者的基因组变异可能会以多种方式导致疾病，包括对炎症途径的影响，神经元和其他细胞产生的屁股或其他潜在毒性分子的神经胶质转换或神经元对应用程序处理的途径的影响，对App Processing的途径的影响，易感性损害，tau高磷酸化，在这种情况下，氧化为氧化2，在这种情况下进行氧化2，在这种情况下进行氧化2，探索了氧化2。并使用HIPSC技术来检验以下假设：至少某些SAD基因组会在人类神经元中引起APP表达，APP加工或TAU磷酸化表型，这些神经元携带了发展SAD的患者的基因组。使用高分辨率分子遗传分析来定义不同的基因组变体如何有助于神经元表型，并可能允许鉴定新的药物靶标和途径，从而为进一步研究提供了原材料，以提供进一步研究的原材料。也可能会产生可能的预测措施和诊断。在这个试点项目中，我们将通过完成两个具体目标来探讨这些问题：1）我们将从5名SAD患者和5个年龄匹配的正常对照（NC）中分别产生3条HIPSC线。 2）我们将从每个HIPSC系列产生纯化的神经元，并测试SAD神经元是否表现出APP表达，APP加工或Tau磷酸化的典型FAD变化。